Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic?
The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome. We used the d...
Gespeichert in:
Veröffentlicht in: | Stroke (1970) 2001-06, Vol.32 (6), p.1330-1335 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1335 |
---|---|
container_issue | 6 |
container_start_page | 1330 |
container_title | Stroke (1970) |
container_volume | 32 |
creator | BERGER, Christian FIORELLI, Marco STEINER, Thorsten SCHÄBITZ, Wolf-Rüdiger BOZZAO, Luigi BLUHMKI, Erich HACKE, Werner VON KUMMER, Rüdiger |
description | The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome.
We used the data set of the European Cooperative Acute Stroke Study (ECASS) II for a post hoc analysis. All patients had a control CT scan after 24 to 96 hours or earlier in case of rapid and severe clinical deterioration. HT was categorized according to radiological criteria: hemorrhagic infarction type 1 and type 2 and parenchymal hematoma type 1 and type 2. The clinical course was prospectively documented with the National Institutes of Health Stroke Scale and the modified Rankin Scale: The independent risk of each type of HT was calculated for clinical deterioration at 24 hours and disability and death at 3 months after stroke onset and adjusted for possible confounding factors such as age, severity of stroke syndrome at baseline, and extent of the ischemic lesion on the initial CT.
Compared with absence of HT, only parenchymal hematoma type 2 was associated with an increased risk for deterioration at 24 hours after stroke onset (adjusted odds ratio, 18; 95% CI, 6 to 56) and for death at 3 months (adjusted odds ratio, 11; 95% CI, 3.7 to 36). All other types of HT did not independently increase the risk of late deterioration.
Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis. It has a distinct radiological feature: it is a dense homogeneous hematoma >30% of the ischemic lesion volume with significant space-occupying effect. |
doi_str_mv | 10.1161/01.STR.32.6.1330 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70920920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74107778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-f5c9b56c01f531449c0588b7cb44de92bf9cb3f5abd1858cdc9ad58aa105f1d13</originalsourceid><addsrcrecordid>eNpdkE1LxDAQhoMo7rp69yRFxFvrTJN0Ey8i4hcsCH6cQ5omWtk2a9Ie_Pdm2QVFCAxhnnlneAg5RigQK7wALF5enwtaFlWBlMIOmSIvWc6qUuySKQCVecmknJCDGD8BoKSC75MJIhVzJvmUPD_Yzofwod9bkw1B99H50Omh9X3mXdZG82G71KqDbvtsaGMcbXaZXcfvbjX4NWgyH7I_36tDsuf0MtqjbZ2Rt7vb15uHfPF0_3hzvchNWj7kjhtZ88oAOk6RMWmAC1HPTc1YY2VZO2lq6riuGxRcmMZI3XChNQJ32CCdkfNN7ir4r9HGQXXpXLtc6t76Mao5yHL9Enj6D_z0Y-jTbQrlXCADyhIEG8gEH2OwTq1C2-nwrRDUWrYCVEm2oqWq1Fp2GjnZ5o51Z5vfga3dBJxtAR2NXrqk17TxTzBQFJL-AN7hh84</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>197814034</pqid></control><display><type>article</type><title>Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic?</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>BERGER, Christian ; FIORELLI, Marco ; STEINER, Thorsten ; SCHÄBITZ, Wolf-Rüdiger ; BOZZAO, Luigi ; BLUHMKI, Erich ; HACKE, Werner ; VON KUMMER, Rüdiger</creator><creatorcontrib>BERGER, Christian ; FIORELLI, Marco ; STEINER, Thorsten ; SCHÄBITZ, Wolf-Rüdiger ; BOZZAO, Luigi ; BLUHMKI, Erich ; HACKE, Werner ; VON KUMMER, Rüdiger</creatorcontrib><description>The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome.
We used the data set of the European Cooperative Acute Stroke Study (ECASS) II for a post hoc analysis. All patients had a control CT scan after 24 to 96 hours or earlier in case of rapid and severe clinical deterioration. HT was categorized according to radiological criteria: hemorrhagic infarction type 1 and type 2 and parenchymal hematoma type 1 and type 2. The clinical course was prospectively documented with the National Institutes of Health Stroke Scale and the modified Rankin Scale: The independent risk of each type of HT was calculated for clinical deterioration at 24 hours and disability and death at 3 months after stroke onset and adjusted for possible confounding factors such as age, severity of stroke syndrome at baseline, and extent of the ischemic lesion on the initial CT.
Compared with absence of HT, only parenchymal hematoma type 2 was associated with an increased risk for deterioration at 24 hours after stroke onset (adjusted odds ratio, 18; 95% CI, 6 to 56) and for death at 3 months (adjusted odds ratio, 11; 95% CI, 3.7 to 36). All other types of HT did not independently increase the risk of late deterioration.
Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis. It has a distinct radiological feature: it is a dense homogeneous hematoma >30% of the ischemic lesion volume with significant space-occupying effect.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/01.STR.32.6.1330</identifier><identifier>PMID: 11387495</identifier><identifier>CODEN: SJCCA7</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Age Factors ; Biological and medical sciences ; Brain Ischemia - complications ; Brain Ischemia - diagnosis ; Brain Ischemia - drug therapy ; Cerebral Hemorrhage - classification ; Cerebral Hemorrhage - diagnosis ; Cerebral Hemorrhage - etiology ; Diagnosis, Differential ; Disease Progression ; Double-Blind Method ; Europe ; Hematoma - classification ; Hematoma - etiology ; Hematoma - pathology ; Humans ; Medical sciences ; Neurology ; Odds Ratio ; Predictive Value of Tests ; Prognosis ; Randomized Controlled Trials as Topic - statistics & numerical data ; Retrospective Studies ; Risk Assessment - statistics & numerical data ; Severity of Illness Index ; Tissue Plasminogen Activator - therapeutic use ; Tomography, X-Ray Computed ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Stroke (1970), 2001-06, Vol.32 (6), p.1330-1335</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jun 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-f5c9b56c01f531449c0588b7cb44de92bf9cb3f5abd1858cdc9ad58aa105f1d13</citedby><cites>FETCH-LOGICAL-c387t-f5c9b56c01f531449c0588b7cb44de92bf9cb3f5abd1858cdc9ad58aa105f1d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1003189$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11387495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BERGER, Christian</creatorcontrib><creatorcontrib>FIORELLI, Marco</creatorcontrib><creatorcontrib>STEINER, Thorsten</creatorcontrib><creatorcontrib>SCHÄBITZ, Wolf-Rüdiger</creatorcontrib><creatorcontrib>BOZZAO, Luigi</creatorcontrib><creatorcontrib>BLUHMKI, Erich</creatorcontrib><creatorcontrib>HACKE, Werner</creatorcontrib><creatorcontrib>VON KUMMER, Rüdiger</creatorcontrib><title>Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic?</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome.
We used the data set of the European Cooperative Acute Stroke Study (ECASS) II for a post hoc analysis. All patients had a control CT scan after 24 to 96 hours or earlier in case of rapid and severe clinical deterioration. HT was categorized according to radiological criteria: hemorrhagic infarction type 1 and type 2 and parenchymal hematoma type 1 and type 2. The clinical course was prospectively documented with the National Institutes of Health Stroke Scale and the modified Rankin Scale: The independent risk of each type of HT was calculated for clinical deterioration at 24 hours and disability and death at 3 months after stroke onset and adjusted for possible confounding factors such as age, severity of stroke syndrome at baseline, and extent of the ischemic lesion on the initial CT.
Compared with absence of HT, only parenchymal hematoma type 2 was associated with an increased risk for deterioration at 24 hours after stroke onset (adjusted odds ratio, 18; 95% CI, 6 to 56) and for death at 3 months (adjusted odds ratio, 11; 95% CI, 3.7 to 36). All other types of HT did not independently increase the risk of late deterioration.
Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis. It has a distinct radiological feature: it is a dense homogeneous hematoma >30% of the ischemic lesion volume with significant space-occupying effect.</description><subject>Age Factors</subject><subject>Biological and medical sciences</subject><subject>Brain Ischemia - complications</subject><subject>Brain Ischemia - diagnosis</subject><subject>Brain Ischemia - drug therapy</subject><subject>Cerebral Hemorrhage - classification</subject><subject>Cerebral Hemorrhage - diagnosis</subject><subject>Cerebral Hemorrhage - etiology</subject><subject>Diagnosis, Differential</subject><subject>Disease Progression</subject><subject>Double-Blind Method</subject><subject>Europe</subject><subject>Hematoma - classification</subject><subject>Hematoma - etiology</subject><subject>Hematoma - pathology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Odds Ratio</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>Risk Assessment - statistics & numerical data</subject><subject>Severity of Illness Index</subject><subject>Tissue Plasminogen Activator - therapeutic use</subject><subject>Tomography, X-Ray Computed</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1LxDAQhoMo7rp69yRFxFvrTJN0Ey8i4hcsCH6cQ5omWtk2a9Ie_Pdm2QVFCAxhnnlneAg5RigQK7wALF5enwtaFlWBlMIOmSIvWc6qUuySKQCVecmknJCDGD8BoKSC75MJIhVzJvmUPD_Yzofwod9bkw1B99H50Omh9X3mXdZG82G71KqDbvtsaGMcbXaZXcfvbjX4NWgyH7I_36tDsuf0MtqjbZ2Rt7vb15uHfPF0_3hzvchNWj7kjhtZ88oAOk6RMWmAC1HPTc1YY2VZO2lq6riuGxRcmMZI3XChNQJ32CCdkfNN7ir4r9HGQXXpXLtc6t76Mao5yHL9Enj6D_z0Y-jTbQrlXCADyhIEG8gEH2OwTq1C2-nwrRDUWrYCVEm2oqWq1Fp2GjnZ5o51Z5vfga3dBJxtAR2NXrqk17TxTzBQFJL-AN7hh84</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>BERGER, Christian</creator><creator>FIORELLI, Marco</creator><creator>STEINER, Thorsten</creator><creator>SCHÄBITZ, Wolf-Rüdiger</creator><creator>BOZZAO, Luigi</creator><creator>BLUHMKI, Erich</creator><creator>HACKE, Werner</creator><creator>VON KUMMER, Rüdiger</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic?</title><author>BERGER, Christian ; FIORELLI, Marco ; STEINER, Thorsten ; SCHÄBITZ, Wolf-Rüdiger ; BOZZAO, Luigi ; BLUHMKI, Erich ; HACKE, Werner ; VON KUMMER, Rüdiger</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-f5c9b56c01f531449c0588b7cb44de92bf9cb3f5abd1858cdc9ad58aa105f1d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Age Factors</topic><topic>Biological and medical sciences</topic><topic>Brain Ischemia - complications</topic><topic>Brain Ischemia - diagnosis</topic><topic>Brain Ischemia - drug therapy</topic><topic>Cerebral Hemorrhage - classification</topic><topic>Cerebral Hemorrhage - diagnosis</topic><topic>Cerebral Hemorrhage - etiology</topic><topic>Diagnosis, Differential</topic><topic>Disease Progression</topic><topic>Double-Blind Method</topic><topic>Europe</topic><topic>Hematoma - classification</topic><topic>Hematoma - etiology</topic><topic>Hematoma - pathology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Odds Ratio</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>Risk Assessment - statistics & numerical data</topic><topic>Severity of Illness Index</topic><topic>Tissue Plasminogen Activator - therapeutic use</topic><topic>Tomography, X-Ray Computed</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BERGER, Christian</creatorcontrib><creatorcontrib>FIORELLI, Marco</creatorcontrib><creatorcontrib>STEINER, Thorsten</creatorcontrib><creatorcontrib>SCHÄBITZ, Wolf-Rüdiger</creatorcontrib><creatorcontrib>BOZZAO, Luigi</creatorcontrib><creatorcontrib>BLUHMKI, Erich</creatorcontrib><creatorcontrib>HACKE, Werner</creatorcontrib><creatorcontrib>VON KUMMER, Rüdiger</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BERGER, Christian</au><au>FIORELLI, Marco</au><au>STEINER, Thorsten</au><au>SCHÄBITZ, Wolf-Rüdiger</au><au>BOZZAO, Luigi</au><au>BLUHMKI, Erich</au><au>HACKE, Werner</au><au>VON KUMMER, Rüdiger</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic?</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>32</volume><issue>6</issue><spage>1330</spage><epage>1335</epage><pages>1330-1335</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><coden>SJCCA7</coden><abstract>The term symptomatic hemorrhage secondary to ischemic stroke implies a clear causal relationship between clinical deterioration and hemorrhagic transformation (HT) regardless of the type of HT. The aim of this study was to assess which type of HT independently affects clinical outcome.
We used the data set of the European Cooperative Acute Stroke Study (ECASS) II for a post hoc analysis. All patients had a control CT scan after 24 to 96 hours or earlier in case of rapid and severe clinical deterioration. HT was categorized according to radiological criteria: hemorrhagic infarction type 1 and type 2 and parenchymal hematoma type 1 and type 2. The clinical course was prospectively documented with the National Institutes of Health Stroke Scale and the modified Rankin Scale: The independent risk of each type of HT was calculated for clinical deterioration at 24 hours and disability and death at 3 months after stroke onset and adjusted for possible confounding factors such as age, severity of stroke syndrome at baseline, and extent of the ischemic lesion on the initial CT.
Compared with absence of HT, only parenchymal hematoma type 2 was associated with an increased risk for deterioration at 24 hours after stroke onset (adjusted odds ratio, 18; 95% CI, 6 to 56) and for death at 3 months (adjusted odds ratio, 11; 95% CI, 3.7 to 36). All other types of HT did not independently increase the risk of late deterioration.
Only parenchymal hematoma type 2 independently causes clinical deterioration and impairs prognosis. It has a distinct radiological feature: it is a dense homogeneous hematoma >30% of the ischemic lesion volume with significant space-occupying effect.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11387495</pmid><doi>10.1161/01.STR.32.6.1330</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0039-2499 |
ispartof | Stroke (1970), 2001-06, Vol.32 (6), p.1330-1335 |
issn | 0039-2499 1524-4628 |
language | eng |
recordid | cdi_proquest_miscellaneous_70920920 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Age Factors Biological and medical sciences Brain Ischemia - complications Brain Ischemia - diagnosis Brain Ischemia - drug therapy Cerebral Hemorrhage - classification Cerebral Hemorrhage - diagnosis Cerebral Hemorrhage - etiology Diagnosis, Differential Disease Progression Double-Blind Method Europe Hematoma - classification Hematoma - etiology Hematoma - pathology Humans Medical sciences Neurology Odds Ratio Predictive Value of Tests Prognosis Randomized Controlled Trials as Topic - statistics & numerical data Retrospective Studies Risk Assessment - statistics & numerical data Severity of Illness Index Tissue Plasminogen Activator - therapeutic use Tomography, X-Ray Computed Vascular diseases and vascular malformations of the nervous system |
title | Hemorrhagic transformation of ischemic brain tissue : Asymptomatic or symptomatic? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A28%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemorrhagic%20transformation%20of%20ischemic%20brain%20tissue%20:%20Asymptomatic%20or%20symptomatic?&rft.jtitle=Stroke%20(1970)&rft.au=BERGER,%20Christian&rft.date=2001-06-01&rft.volume=32&rft.issue=6&rft.spage=1330&rft.epage=1335&rft.pages=1330-1335&rft.issn=0039-2499&rft.eissn=1524-4628&rft.coden=SJCCA7&rft_id=info:doi/10.1161/01.STR.32.6.1330&rft_dat=%3Cproquest_cross%3E74107778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=197814034&rft_id=info:pmid/11387495&rfr_iscdi=true |